Gregory Korbel
Chief Operating Officer chez Atrin Pharmaceuticals, Inc.
Fortune : 7 178 $ au 31/03/2024
Profil
Gregory A.
Korbel is currently the Chief Operating Officer at Atrin Pharmaceuticals, Inc. He previously worked as the Director of Research Operations at Johnson & Johnson.
From 2012 to 2015, he was the Director of Business Development & Operations at Novira Therapeutics LLC.
From 2022 to 2023, he was the Chief Operating Officer & Senior Vice President at Aprea Therapeutics, Inc. Korbel holds a doctorate from Harvard University, an undergraduate degree from Vanderbilt University, and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APREA THERAPEUTICS, INC.
0,02% | 26/06/2023 | 1 073 ( 0,02% ) | 7 178 $ | 31/03/2024 |
Postes actifs de Gregory Korbel
| Sociétés | Poste | Début |
|---|---|---|
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Chief Operating Officer | - |
Anciens postes connus de Gregory Korbel
| Sociétés | Poste | Fin |
|---|---|---|
| APREA THERAPEUTICS, INC. | Chief Operating Officer | 31/03/2023 |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Chief Operating Officer | 01/12/2015 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Formation de Gregory Korbel
| Harvard University | Doctorate Degree |
| Vanderbilt University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |
